Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 8/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7900252 | 0.85 | GRIA2 (0.50) | GRIA2BDKRB1MAOB | |
| SCHEMBL7900317 | 0.84 | GRIA2 (0.49) | GRIA2TRPV1BDKRB1MAOBCCR2 | |
| SCHEMBL7888226 | 0.83 | GRIA2 (0.49) | GRIA2BDKRB1MAOB | |
| SCHEMBL28795623 | 0.82 | GRIA2 (0.48) | GRIA2MAOB | |
| SCHEMBL7898009 | 0.82 | GRIA2 (0.48) | GRIA2MAOBCCR2 | |
| SCHEMBL7890611 | 0.82 | GRIA2 (0.48) | GRIA2BDKRB1 | |
| SCHEMBL7898805 | 0.81 | GRIA2 (0.47) | GRIA2KCNH2 | |
| SCHEMBL7896164 | 0.81 | GRIA2 (0.49) | GRIA2TRPV1KCNH2 | |
| SCHEMBL11900094 | 0.80 | GRIA2 (0.52) | GRIA2TRPV1 | |
| SCHEMBL7896403 | 0.80 | GRIA2 (0.52) | GRIA2KCNH2MAOBHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| CN-102365265-A | Indane derivatives | ORGANON NV | 2012-02-29 | — | — | CN | disclosed |
| WO-2010115952-A1 | INDANE DERIVATIVES | N.V. ORGANON (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202781-A1 | INDANE DERIVATIVES | CHRNA5, CHRNA2, GRIK5 | GRIA2 24/4885TRPV1 227/4885KCNH2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.